MedTrace Logo

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-10-19

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that Besivance is equal to Vigamox in safety and tolerance when used prophylactically in subjects undergoing routine cataract surgery.

Conditions

  • Corneal Health
  • Cataract Surgery

Interventions

DRUG

besivance

topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery

DRUG

vigamox

topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery

Sponsors & Collaborators

  • Ophthalmology Associates, St Louis

    collaborator OTHER

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Ophthalmology Consultants, Ltd.

    lead OTHER

Principal Investigators

  • Ranjan Maholtra, MD · Ophthalmology Associates

  • Joseph Gira, MD · Ophthalmology Consultants

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455233 on ClinicalTrials.gov